Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC lessened its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 30.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 776,852 shares of the biopharmaceutical company’s stock after selling 338,967 shares during the period. Corient Private Wealth LLC’s holdings in Bristol-Myers Squibb were worth $39,860,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of BMY. Addison Advisors LLC boosted its position in shares of Bristol-Myers Squibb by 6.6% during the 3rd quarter. Addison Advisors LLC now owns 3,120 shares of the biopharmaceutical company’s stock worth $181,000 after acquiring an additional 192 shares in the last quarter. Symphony Financial Ltd. Co. boosted its holdings in Bristol-Myers Squibb by 4.1% in the third quarter. Symphony Financial Ltd. Co. now owns 4,980 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 194 shares in the last quarter. AMG National Trust Bank increased its stake in Bristol-Myers Squibb by 1.0% in the third quarter. AMG National Trust Bank now owns 19,685 shares of the biopharmaceutical company’s stock valued at $1,143,000 after purchasing an additional 201 shares during the last quarter. Westside Investment Management Inc. lifted its position in shares of Bristol-Myers Squibb by 2.9% during the 4th quarter. Westside Investment Management Inc. now owns 7,156 shares of the biopharmaceutical company’s stock worth $367,000 after buying an additional 204 shares during the last quarter. Finally, Fulton Breakefield Broenniman LLC boosted its holdings in shares of Bristol-Myers Squibb by 4.6% in the 4th quarter. Fulton Breakefield Broenniman LLC now owns 4,744 shares of the biopharmaceutical company’s stock valued at $243,000 after buying an additional 209 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BMY has been the subject of a number of research reports. Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. BMO Capital Markets cut their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Barclays decreased their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. Finally, Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price target for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Price Performance

Bristol-Myers Squibb stock opened at $42.35 on Thursday. The stock’s 50 day moving average price is $48.24 and its 200 day moving average price is $49.80. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. Bristol-Myers Squibb has a 1-year low of $41.91 and a 1-year high of $67.16.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. During the same period in the prior year, the company posted $2.05 EPS. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. Equities analysts anticipate that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.67%. The ex-dividend date was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.